

boundaries, in the first untitled table that begins with "Waterbody Limits" column, which appears on pages 25856

through 25857, is corrected to read as follows:

Waterbody	Waterbody/Limits	Area (acres)
Stony Creek .....	39.1723° N, 76.5171° W to 39.1725° N, 76.5126° W .....	677
Rock Creek .....	39.1614° N, 76.5004° W to 39.1625° N, 76.4862° W .....	524
South Shore, Patapsco River .....	39.1472° N, 76.4589° W to 39.1471° N, 76.4588° W .....	2
Bodkin Creek .....	39.1346° N, 76.4398° W to 39.1320° N, 76.4384° W .....	609
Magothy and Little Magothy Rivers .....	39.0592° N, 76.4332° W to 39.0462° N, 76.4295° W .....	5,879
Podickory Creek .....	39.0328° N, 76.4040° W to 39.0318° N, 76.4049° W .....	9
Sandy Point/Mezick Ponds .....	39.0087° N, 76.4032° W to 39.0086° N, 76.4037° W .....	47
Whitehall Bay .....	38.9748° N, 76.4547° W to 38.9871° N, 76.4268° W .....	1,599
Severn River .....	38.9747° N, 76.4547° W to 38.9411° N, 76.4504° W .....	7,497
Oyster Creek .....	38.9274° N, 76.4638° W to 38.9273° N, 76.4634° W .....	34
Fishing Creek .....	38.9148° N, 76.4591° W to 38.9073° N, 76.4602° W .....	228
South River .....	38.9073° N, 76.4602° W to 38.8850° N, 76.4910° W .....	5,904
West and Rhode Rivers .....	38.8850° N, 76.4910° W to 38.8531° N, 76.4959° W .....	4,370
Total Area .....	.....	27,379

Dated: September 2, 2021.

**Diana Esher,**

*Acting Regional Administrator, EPA Region III.*

[FR Doc. 2021-19601 Filed 9-10-21; 8:45 am]

**BILLING CODE 6560-50-P**

## EXPORT-IMPORT BANK

[Public Notice 2021-3027]

### Agency Information Collection Activities: Comment Request

**AGENCY:** Export-Import Bank of the United States.

**ACTION:** Submission for OMB review and comments request.

**SUMMARY:** The Export-Import Bank of the United States (EXIM), as a part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal Agencies to comment on the proposed information collection, as required by the Paperwork Reduction Act of 1995.

**DATES:** Comments must be received on or before October 13, 2021 to be assured of consideration.

**ADDRESSES:** Comments may be submitted electronically on [WWW.REGULATIONS.GOV](http://WWW.REGULATIONS.GOV) or by mail to Edward Coppola, Export-Import Bank of the United States, 811 Vermont Ave. NW, Washington, DC 20571.

The form can be viewed at: <https://www.exim.gov/sites/default/files/pub/pending/eib11-04.pdf>.

**FOR FURTHER INFORMATION CONTACT:** To request additional information, please Edward Coppola [Edward.Coppola@exim.gov](mailto:Edward.Coppola@exim.gov). 202-565-3717.

Form can be viewed at <https://www.exim.gov/sites/default/files/pub/pending/eib92-79.pdf>.

### SUPPLEMENTARY INFORMATION:

*Title and Form Number:* EIB 92-79 Broker Registration Form.

*Form Title:* EIB 92-79 Broker Registration Form.

*OMB Number:* 3048-0024.

*Type of Review:* Regular.

*Need and Use:* This form is used by insurance brokers to register with Export Import Bank. The form provides Export Import Bank staff with the information necessary to make a determination of the eligibility of the broker to receive commission payments under Export Import Bank's credit insurance programs.

Our customers will be able to submit this form on paper or electronically. This form is used by insurance brokers to register with Export-Import Bank. It provides EXIM staff with the information necessary to make a determination of the eligibility of the broker to receive commission payments under Export-Import Bank's credit insurance programs.

*Affected Public:* This form affects entities engaged in brokering export credit insurance policies.

*Annual Number of Respondents:* 50.

*Estimated Time per Respondent:* 15 minutes.

*Frequency of Reporting or Use:* Once every three years.

*Government Expenses:*

*Review Time per Response:* 2 hours.

*Reviewing Time per Year:* 100 hours.

*Average Wages per Hour:* \$42.50.

*Average Cost per Year:* \$4,250.

*Benefits and Overhead:* 20%.

*Total Government Cost:* \$5,100.

**Bassam Doughman,**  
*IT Specialist.*

[FR Doc. 2021-19633 Filed 9-10-21; 8:45 am]

**BILLING CODE 6690-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

[Document Identifier: CMS-R-308]

### Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** Centers for Medicare & Medicaid Services, Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**DATES:** Comments on the collection(s) of information must be received by the OMB desk officer by *October 13, 2021*.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of the following:

1. Access CMS’ website address at website address at: <https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.html>.

**FOR FURTHER INFORMATION CONTACT:** William Parham at (410) 786-4669.

**SUPPLEMENTARY INFORMATION:** Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term “collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires federal agencies to publish a 30-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice that summarizes the following proposed collection(s) of information for public comment:

1. *Type of Information Collection Request:* Revision of a currently approved collection; *Title of Information Collection:* State Children’s Health Insurance Program and Supporting Regulations; *Use:* States must submit title XXI plans and amendments for approval by the Secretary. We use the plan and its subsequent amendments to determine if the state has met the requirements of title XXI. Information provided in the state plan, state plan amendments, and from the other information we are collecting will be used by advocacy groups, beneficiaries, applicants, other governmental agencies, providers groups, research organizations, health care corporations, health care consultants. States will use the

information collected to assess state plan performance, health outcomes and an evaluation of the amount of substitution of private coverage that occurs as a result of the subsidies and the effect of the subsidies on access to coverage.

This iteration proposes to: Remove certain reporting requirements, revise the information collection instrument, and revise reporting instructions. We are also proposing to change the respondent’s occupation and hourly wage, adjust the number of respondents, and adjust the number of enrollees by using more recent data. *Form Number:* CMS-R-308 (OMB control number: 0938-0841); *Frequency:* Yearly, Once, and Occasionally; *Affected Public:* State, Local, or Tribal Governments; *Number of Respondents:* 51; *Total Annual Responses:* 9,677,272; *Total Annual Hours:* 485,940. (For policy questions regarding this collection contact Cassie Lagorio at 410-786-4554.)

Dated: September 7, 2021.

**William N. Parham, III,**

*Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.*

[FR Doc. 2021-19599 Filed 9-10-21; 8:45 am]

**BILLING CODE 4120-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2021-N-0008]

### Blood Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Blood Products Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA’s regulatory issues. Members will participate via teleconference. At least one portion of the meeting will be closed to the public.

**DATES:** The meeting will be held on November 4, 2021, from 9:30 a.m. to 5:20 p.m. Eastern Time.

**ADDRESSES:** Please note that due to the impact of the COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. The online web conference meeting will be available at the following link on the

day of the meeting: <https://youtu.be/2Xz4YzkwNDs>.

### FOR FURTHER INFORMATION CONTACT:

Christina Vert or Joanne Lipkind, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6268, Silver Spring, MD 20993-0002, 240-402-8054, [Christina.Vert@fda.hhs.gov](mailto:Christina.Vert@fda.hhs.gov), or 240-402-8106, [Joanne.Lipkind@fda.hhs.gov](mailto:Joanne.Lipkind@fda.hhs.gov), respectively, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s website at <https://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

### SUPPLEMENTARY INFORMATION:

**Agenda:** The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On November 4, 2021, for Topic I, the committee will meet in open session to hear an overview of the research programs of the Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER). For Topic II, the committee will meet in open session to hear an overview of the research programs of the Laboratory of Cellular Hematology, Division of Blood Components and Devices, Office of Blood Research and Review (OBRR), CBER. For Topic III, the committee will meet in open session to hear an overview of the research programs of the Laboratory of Emerging Pathogens, Division of Emerging & Transfusion Transmitted Diseases, OBRR, CBER. After the open sessions, the meeting will be closed to the public for committee deliberations.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s website after the meeting. Background material is